

State Legislative & Policy Update

PRESENTER Brian Henderson

Director, State Government Affairs Hart Health Strategies

Utilization Management Reform




Step Therapy

Generally

- Provider can override a step therapy protocol under certain circumstances
- 24/72 hour determination timeframe (varies)
- Minimum evidentiary standard for creating a protocol

Key Challenges

- Awareness, use, application
 - CSRO Resources
 - New Education Campaigns
 - Interaction between






Prior Authorization – Gold Cards

• In general:

- Exempts physicians from prior authorization requirements for a *specific service* if a certain percentage of authorizations are approved (80-95%) for that service, for that insurer or health maintenance organization
- Requires peer to peer consultation prior to issuing a denial
- Appeals process for inappropriate denial of exemption
- Prohibition on retroactive claw backs on exempted physician services except in case of fraud






Prior Authorization – Gold Cards

Qualifying for an exemption:

- Initial determination: All requests analyzed, but no fewer than five
- Re-evaluation: Random sample of 5 20 requests from prior 6 months
- One provider cannot rely on another provider's exemption
- Consideration of practice level vs. individual physician or service grouping instead of individual service
 - Exemption based on drug class or by indication?






Prior Authorization – Gold Cards

CSRO Survey (TX):

- 88% did not receive any exemption
- Of those receiving an exemption:
 - 3/7: Did reduce burden
 - 3/7: Did not reduce burden
 - 1/7: Somewhat reduced burden
 - 4/7: keeping track of exemptions was itself burdensome
 - 7/7 lack of clarity on whether non-prior authorization utilization management was still required.

Key Challenges:

- Treatment interval, variety, volume
- Variety of insurers
- Tracking exemptions
- Concurrent utilization management requirements (step therapy)




Celebrating **20 years** of serving as a **voice for the rheumatology community**, working to ensure patients have access to care.

The War on Copay & Other Assistance

Accumulator Adjustment Programs:

- Payers: Not counting third party assistance towards a patient's deductible
- Key Challenges:
 - Patient OOP increases
 - Non-medical switching
- Policy:
 - Require insurers to count third party payments towards patient deductibles and other OOP obligations
 - Carveout for generics/interchangeable biosimilars
 - Carveout for HSS eligible HDHPs





The War on Copay & Other Assistance

Maximizer Programs:

- Payers:
 - Ascertaining amount of copay assistance available
 - Altering patient benefits to conform to available assistance
 - Distributing new cost sharing obligations over the year
- Key Challenges:
 - Avoids copay "surprise"
 - Challenges sustainability of assistance programs
 - Increased patient OOP costs
- Policy:

8

• Must close federal loophole, potential state level activity to fix

The War on Copay & Other Assistance

Alternative Funding Programs:


- Third Party Administrators:
 - Employer: carves out specialty drug(s) from coverage under plan
 - Third Party Administrators: apply for manufacturer or charitable foundation assistance to cover drug costs
 - Patient: may or may not receive assistance to cover drug cost
- Key Challenges:
 - Patient access/ OOP costs
 - Challenges sustainability of assistance programs
 - Drug importation
- Policy:

9

- Potential legislation to prevent spillover of these programs
- TX HB 4800 allowing Alternative Funding programs

Non-medical Switching

- Two policies:
 - Year-over-year (Grandfathering)
 - Mid-year switching protection




reated with mapchart.ne



• Three main types of bills:

12

- Safety and logistics guidelines
- Protecting patient choice of provider, coverage, and OOP costs
- Patient choice, coverage, OOP costs, authorization for service, provider reimbursement, prohibition on requirement to dispense from a selected pharmacy




Created with mapchart.r



Two new wins!

- North Dakota
- Texas:
 - Excludes hospitals
 - Prohibits switching from medical benefit to pharmacy benefit



CSRO

Created with manchart.ne


Additional policy evolutions: New Hampshire:

 Reimbursement consistent with "similarly situated" network participants

Oregon:

14

 Choice between participating as a specialty pharmacy or accepting white bagging





PBM Reform






Rebate Pass Through

Policy:

- Patient cost shares reduced by percentage of rebates received in conjunction with their utilization (50 -100%)
- Some legislation only requires pass through of rebates to plan sponsor/insurer




Celebrating **20 years** of serving as a **voice for the rheumatology community**, working to ensure patients have access to care.

Transparency

New Policy Evolution:

- Legislation to extend transparency to PBM affiliated/owned organizations
- Rebate aggregators

17





Biosimilars

18




Biosimilars

Step Therapy

19

- Allow insurer to require trial and failure of a non-interchangeable biosimilar product even when patient qualifies for an exception (stable provision)
- Pharmacy Level Substitution
 - Allow pharmacist to substitute noninterchangeable product
- Eliminate separate designations (Federal)
 - Automatically confer interchangeability status to all biosimilars



CSRO

Drug Affordability

20



Drug Affordability Boards

• Upper Price Limit

• Limitation on both purchase and reimbursement for a prescription drug

Maximum Fair Price

- State imports MFP negotiated by federal government
- Provider cannot seek reimbursement at a rate higher than the MFP
- MFP *does not* include administration payment




Biomarker Testing





Biomarker Testing

- Coverage of a biomarker test required under certain circumstances:
 - $\circ~$ CMS or MAC NCD or LCA
 - Nationally recognized clinical practice guidelines
 - Labeled indications



CSRO

eated with mapchart.n